Ayala Pharmaceuticals (NASDAQ:ADXS) Now Covered by Analysts at StockNews.com

by · The Cerbat Gem

StockNews.com initiated coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS – Free Report) in a research report released on Monday morning. The firm issued a sell rating on the stock.

Ayala Pharmaceuticals Stock Performance

NASDAQ:ADXS opened at $0.03 on Monday. Ayala Pharmaceuticals has a one year low of $0.00 and a one year high of $1.49. The business’s 50-day simple moving average is $0.05 and its 200 day simple moving average is $0.12. The stock has a market cap of $1.15 million, a price-to-earnings ratio of 0.00 and a beta of 1.81.

About Ayala Pharmaceuticals

(Get Free Report)

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.

Further Reading